Alkermes plc (ALKS)

NASDAQ: ALKS · IEX Real-Time Price · USD
28.64
-0.15 (-0.52%)
Jan 31, 2023, 4:00 PM EST - Market closed
-0.52%
Market Cap 4.71B
Revenue (ttm) 1.13B
Net Income (ttm) -129.14M
Shares Out 164.31M
EPS (ttm) -0.78
PE Ratio n/a
Forward PE 588.24
Dividend n/a
Ex-Dividend Date n/a
Volume 1,169,340
Open 28.79
Previous Close 28.79
Day's Range 28.53 - 29.04
52-Week Range 21.75 - 32.79
Beta 0.56
Analysts Buy
Price Target 32.03 (+11.84%)
Earnings Date Feb 15, 2023

About ALKS

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia a... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 16, 1991
Employees 2,211
Stock Exchange NASDAQ
Ticker Symbol ALKS
Full Company Profile

Financial Performance

In 2021, Alkermes's revenue was $1.17 billion, an increase of 13.00% compared to the previous year's $1.04 billion. Losses were -$48.17 million, -56.55% less than in 2020.

Financial Statements

Analyst Forecast

According to 16 analysts, the average rating for ALKS stock is "Buy." The 12-month stock price forecast is $32.03, which is an increase of 11.84% from the latest price.

Price Target
$32.03
(11.84% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Alkermes Awarded Innovation Passport Designation by the MHRA (UK) for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma

— Designation Marks Entry Point into MHRA's Innovative Licensing and Access Pathway (ILAP) Program in the UK —   DUBLIN , Jan. 17, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that...

2 weeks ago - PRNewsWire

Alkermes to Present at the 41st Annual J.P. Morgan Healthcare Conference

DUBLIN , Dec. 28, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 41st Annual J.P. ...

1 month ago - PRNewsWire

Alkermes (ALKS) Up 4.4% Since Last Earnings Report: Can It Continue?

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock?

2 months ago - Zacks Investment Research

Alkermes to Participate in the BofA Securities 2022 Biotech SMID Cap Conference

DUBLIN , Nov. 30, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat as part of the BofA Securities 2022 Biotech SMID Cap Conference o...

2 months ago - PRNewsWire

How Alkermes (ALKS) Stock Stands Out in a Strong Industry

Alkermes (ALKS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

2 months ago - Zacks Investment Research

Alkermes to Participate in the 5th Annual Evercore ISI HealthCONx Conference

DUBLIN , Nov. 22, 2022 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on Tuesday,...

2 months ago - PRNewsWire

Alkermes to Participate in the Stifel Healthcare Conference

DUBLIN , Nov. 8, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Stifel 2022 Healthcare Conference on Tuesday, Nov. 15, 2022...

3 months ago - PRNewsWire

Alkermes (ALKS) Q3 Earnings Meet Estimates, Revenues Miss

Alkermes' (ALKS) earnings meet estimates in the third quarter of 2022 while revenues miss the same. The company tightens total revenue guidance for 2022.

3 months ago - Zacks Investment Research

Alkermes (ALKS) Q3 Earnings Match Estimates

Alkermes (ALKS) delivered earnings and revenue surprises of 0% and 8.02%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Alkermes plc Reports Third Quarter 2022 Financial Results

—  Third Quarter Revenues of $252.4 Million Reflect Strong Year-Over-Year Growth of Proprietary Commercial Product Portfolio — —  GAAP Loss per Share of $0.39 and Non-GAAP Earnings per Share of $0. 02...

3 months ago - PRNewsWire

Alkermes plc Announces Intent to Separate Oncology Business

— Alkermes to Focus on Profitable Growth of Pure-Play, Commercial-Stage Neuroscience Business — — Separation Expected to Unlock Value Through Sharpened Strategic Focus, Simplified Capital Allocation D...

3 months ago - PRNewsWire

Alkermes Announces Recipients of 2022 Alkermes Inspiration Grants® Program

–  6th Installment of Competitive Grants Program Awards Funding to Nine Innovative Programs Focused on People Living with Addiction, Serious Mental Illness or Cancer – DUBLIN , Oct. 27, 2022 /PRNewswi...

3 months ago - PRNewsWire

Alkermes to Report Third Quarter Financial Results on Nov. 2, 2022

DUBLIN , Oct. 26, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (12:00 p.m.

3 months ago - PRNewsWire

Alkermes, Allakos See Activist Action

These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities.

Other symbols: ALLK
3 months ago - Market Watch

Alkermes Announces Launch of 5th Annual Alkermes Pathways Research Awards® Program

-- Competitive Grant Program to Offer Individual Grants of Up to $100,000 per Project -- -- Application Period Open Until Nov. 30, 2022 -- DUBLIN , Sept. 28, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq:...

4 months ago - PRNewsWire

Alkermes Showcases Research from Psychiatry Portfolio at Psych Congress

̶  Clinical, Epidemiology and Health Economics and Outcomes Research Shared at Key Psychiatry Conference  ̶ DUBLIN , Sept. 20, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the pres...

4 months ago - PRNewsWire

GSK NDA for Myelofibrosis Candidate Gets FDA Acceptance

GSK's NDA for momelotinib for treating myelofibrosis was based on data from key phase III studies, including the pivotal MOMENTUM study.

Other symbols: EDITGSKIMVT
5 months ago - Zacks Investment Research

Are Medical Stocks Lagging Alkermes (ALKS) This Year?

Here is how Alkermes (ALKS) and Elevance Health (ELV) have performed compared to their sector so far this year.

6 months ago - Zacks Investment Research

Alkermes (ALKS) Could Find Support Soon, Here's Why You Should Buy the Stock Now

Alkermes (ALKS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall ...

6 months ago - Zacks Investment Research

3 Companies Growing Revenue Fast

S&P 500 stocks have posted average growth of 6.54% in annual total revenue from 2017 to 2021. The benchmark index for the U.S. stock market closed at 4,122.47 on Tuesday, up nearly 70% over the past f...

Other symbols: DNLINVAX
6 months ago - GuruFocus

Alkermes (ALKS) Loses 16.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Alkermes (ALKS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates ...

6 months ago - Zacks Investment Research

Alkermes' (ALKS) Earnings & Revenues Surpass Estimates in Q2

Alkermes (ALKS) beat estimates for both earnings and sales in the second quarter of 2022. The company narrows sales guidance for Vivitrol and Aristada.

6 months ago - Zacks Investment Research

Alkermes (ALKS) Q2 Earnings and Revenues Top Estimates

Alkermes (ALKS) delivered earnings and revenue surprises of 50% and 1.13%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Alkermes plc Reports Second Quarter 2022 Financial Results

—    Second Quarter Revenues of $276.2 Million Reflect Strong Growth in Proprietary Net Sales — —    GAAP Loss per Share of $0.18 and Non-GAAP Earnings per Share of $0. 06 — —    Raises Financial Expe...

6 months ago - PRNewsWire